In this episode of Medsider Radio, we caught up with the  HealthQuest Capital Founder,  Garheng Kong, who worked at GlaxoSmithKline, McKinsey, and TherOx before transitioning into healthcare investing with Intersouth Partners and Sofinnova. 

Garheng’s resume is broad and deep. He has earned numerous degrees from two of the nation’s most prestigious universities — Stanford and Duke — and funded an equally impressive collection of healthcare companies throughout his career. 

Garheng and his team see up to 1,000 investment opportunities in any given year. The experience has taught him how to assess which ones are right for the firm, and which he can afford to let go of. 

In this interview, Garheng shares keen insights for startups and innovators preparing to pursue funding, along with observations about how the healthcare industry has shifted thanks to the global COVID-19 pandemic. Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. 

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Garheng if you'd instead read it.